CDKI R547

An orally bioavailable diaminopyrimidine compound and a cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. CDKs are ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and are frequently overexpressed in cancerous cells. R547 selectively binds to and inhibits CDKs, especially CDK1/cyclin B, CDK2/cyclin E, and CDK4/cyclin D1. The inhibition of CDKs results in cell cycle arrest, inhibition of tumor cell proliferation, and induction of apoptosis. By inhibiting CDK activity, R547 also reduces phosphorylation of the retinoblastoma (Rb) protein, thereby preventing activation of transcription factor E2F and leading to further suppression of tumor cell proliferation. (NCI Thesaurus)

YOU MAY ALSO LIKE

CDKI AT7519

An orally bioavailable small molecule with potential antineoplastic activity. AT7519M selectively binds to and inhibits cyclin dependent kinases (CDKs), which may result…

CDK8 wt Allele

Human CDK8 wild-type allele is located in the vicinity of 13q12 and is approximately 151 kb in length. This allele, which encodes…

CDK8 Gene

This gene plays a role in transcriptional regulation.

CDK7 wt Allele

Human CDK7 wild-type allele is located in the vicinity of 5q12.1 and is approximately 78 kb in length. This allele, which encodes…

CDK7 Gene

This gene is involved in the regulation of the cell cycle and RNA polymerase II-mediated transcription.

CDK6/MLL Fusion Protein

A fusion protein encoded by the CDK6/MLL fusion gene. This protein is comprised of the N-terminal protein kinase domain of the cyclin-dependent…